среда, 25 января 2017 г.

Alcon Goes From Gem Worth Over $50 Billion to Drag for Novartis

Alcon Goes From Gem Worth Over $50 Billion to Drag for Novartis


Once a crown jewel that cost Novartis AG more than $50 billion, the Alcon eye-care business has now become an albatross for the Swiss health-care behemoth. In what appeared to be an admission of defeat, Europe's second-biggest drugmaker on Wednesday said it was considering all options for the embattled division, including a spinoff or initial public offering.



from Biotech News